

Hepatitis C virus infection in USA: an estimate of true p

Liver International

31, 1090-1101

DOI: [10.1111/j.1478-3231.2011.02494.x](https://doi.org/10.1111/j.1478-3231.2011.02494.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. <i>Liver International</i> , 2011, 31, 4-17.	1.9	42
2	The global health burden of hepatitis C virus infection. <i>Liver International</i> , 2011, 31, 1-3.	1.9	121
3	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011, 31, 30-60.	1.9	333
4	What Is Killing People with Hepatitis C Virus Infection?. <i>Seminars in Liver Disease</i> , 2011, 31, 331-339.	1.8	122
5	Epidemiological Pattern of Hepatitis B and Hepatitis C as Etiological Agents for Hepatocellular Carcinoma in Iran and Worldwide. <i>Hepatitis Monthly</i> , 2012, 12, e6894.	0.1	61
6	Impact of Peginterferon Alpha and Ribavirin Treatment on Lipid Profiles and Insulin Resistance in Hepatitis C Virus/HIV-Coinfected Persons: The AIDS Clinical Trials Group A5178 Study. <i>Clinical Infectious Diseases</i> , 2012, 55, 631-638.	2.9	14
7	Symptom Status Predicts Patient Outcomes in Persons with HIV and Comorbid Liver Disease. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-11.	0.3	4
8	Nosocomial Hepatitis C: More of a Hidden Epidemic. <i>Annals of Internal Medicine</i> , 2012, 156, 534.	2.0	4
9	Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 859-870.	4.6	276
10	Hepatitis in the Elderly: Still a Scourge. <i>The Consultant Pharmacist</i> , 2012, 27, 472-481.	0.4	2
11	Prevalence, Distribution, and Correlates of Hepatitis C Virus Infection among Homeless Adults in Los Angeles. <i>Public Health Reports</i> , 2012, 127, 407-421.	1.3	69
12	Demographics of hepatitis C virus today. <i>Clinical Liver Disease</i> , 2012, 1, 2-5.	1.0	1
13	Hepatitis C viral infection in drug users. <i>Clinical Liver Disease</i> , 2012, 1, 81-83.	1.0	0
14	The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. <i>Cancer</i> , 2012, 118, 6226-6233.	2.0	56
15	Hepatitis C Virus Prevention, Care, and Treatment: From Policy to Practice. <i>Clinical Infectious Diseases</i> , 2012, 55, S58-S63.	2.9	36
16	Economic burden of hepatitis C-associated diseases in the United States. <i>Journal of Viral Hepatitis</i> , 2012, 19, 153-160.	1.0	63
17	Hepatitis C virus-specific immune responses in noninjecting drug users. <i>Journal of Viral Hepatitis</i> , 2012, 19, 554-559.	1.0	8
18	HCV In At Risk Populations: Who Can be Treated and How?. <i>Current Hepatitis Reports</i> , 2012, 11, 1-9.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Epidemiology and natural history of HCV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 553-562.	8.2	833
20	Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. <i>BMC Infectious Diseases</i> , 2013, 13, 234.	1.3	29
21	Treating Chronic Hepatitis C Viral Infection: Rethinking Dose Reduction Strategies for PEG-IFN and Ribavirin in the Setting of New Direct Acting Agents. <i>Current Hepatitis Reports</i> , 2013, 12, 13-19.	0.3	0
22	An anonymous unlinked sero-prevalence survey of HIV/HCV in an urban Emergency Department. <i>Journal of Clinical Virology</i> , 2013, 58, e19-e23.	1.6	7
23	Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 124-133.	1.9	41
24	Detailed Computational Study of the Active Site of the Hepatitis C Viral RNA Polymerase to Aid Novel Drug Design. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 3031-3043.	2.5	27
25	The Two-Way Relationship Between Medical Illness and Late-Life Depression. <i>Psychiatric Clinics of North America</i> , 2013, 36, 533-544.	0.7	18
26	Treatment as prevention and cure towards global eradication of hepatitis C virus. <i>Trends in Microbiology</i> , 2013, 21, 625-633.	3.5	56
27	Chronic hepatitis C virus (HCV) disease burden and cost in the United States. <i>Hepatology</i> , 2013, 57, 2164-2170.	3.6	397
28	The Role of Public Health in an Era of All-Oral Therapy for Hepatitis C Infection. <i>Current Hepatitis Reports</i> , 2013, 12, 220-226.	0.3	0
29	Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 554-555.	1.9	1
30	The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States. <i>Clinics in Liver Disease</i> , 2013, 17, 1-11.	1.0	52
31	Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy. <i>Journal of Infectious Diseases</i> , 2013, 207, S33-S39.	1.9	90
32	Thyroid Disease in Chronic Hepatitis C Infection Treated With Combination Interferon- α and Ribavirin: Management Strategies and Future Perspective. <i>Endocrine Practice</i> , 2013, 19, 292-300.	1.1	14
34	Validation of a solid-phase electrochemical array for genotyping hepatitis C virus. <i>Experimental and Molecular Pathology</i> , 2013, 95, 18-22.	0.9	19
35	Depression and Fatigue in Chronic Hepatitis C Patients With and Without HIV Co-Infection. <i>Psychosomatics</i> , 2013, 54, 466-471.	2.5	14
36	Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45,000 HCV-infected, evaluated patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 473-481.	1.9	42
37	Best strategies for global HCV eradication. <i>Liver International</i> , 2013, 33, 68-79.	1.9	97

#	ARTICLE	IF	CITATIONS
38	The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. <i>Hepatology</i> , 2013, 58, 54-64.	3.6	71
39	Diabetes and Infections-Hepatitis C: Is There Type 2 Diabetes Excess in Hepatitis C Infection?. <i>Current Diabetes Reports</i> , 2013, 13, 428-434.	1.7	10
42	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1878-1887.	13.9	1,605
43	Association of Chronic Liver Disease with Depression: A Population-Based Study. <i>Psychosomatics</i> , 2013, 54, 52-59.	2.5	79
44	Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis. <i>Clinical Infectious Diseases</i> , 2013, 56, 806-816.	2.9	127
45	Restoration of the Activated Rig-I Pathway in Hepatitis C Virus (HCV) Replicon Cells by HCV Protease, Polymerase, and NS5A Inhibitors <i>In Vitro</i> at Clinically Relevant Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4417-4426.	1.4	11
46	Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy. <i>Clinical Infectious Diseases</i> , 2013, 56, 1466-1470.	2.9	10
47	Protease Inhibitors for Hepatitis C: Economic Implications. <i>Pharmacoeconomics</i> , 2013, 31, 739-751.	1.7	4
48	Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States. <i>Clinical Infectious Diseases</i> , 2013, 56, 1382-1393.	2.9	80
49	Regional and global summary estimates of antibody to hepatitis C virus prevalence in detainee populations: Seeing the forest and the trees?. <i>Hepatology</i> , 2013, 58, 1197-1199.	3.6	2
50	IL28B Polymorphism, Pretreatment CXCL10, and HCV RNA Levels Predict Treatment Response in Racially Diverse HIV/HCV Coinfected and HCV Monoinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 9-16.	0.9	13
51	Evaluation of the Hepatitis C Virus-Infected Patient: The Initial Encounter. <i>Clinical Infectious Diseases</i> , 2013, 56, 853-860.	2.9	6
52	Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6097-6105.	1.4	22
53	A nationwide seroepidemiology of hepatitis C virus infection in South Korea. <i>Liver International</i> , 2013, 33, 586-594.	1.9	81
54	Características demográficas actuales del virus de la hepatitis C. <i>Clinical Liver Disease</i> , 2013, 2, S12A-S15A.	1.0	0
55	Estimating HCV Prevalence at the State Level: A Call to Increase and Strengthen Current Surveillance Systems. <i>American Journal of Public Health</i> , 2013, 103, 1402-1405.	1.5	7
56	KSHV/HHV8-negative Effusion-based Lymphoma, a Distinct Entity Associated With Fluid Overload States. <i>American Journal of Surgical Pathology</i> , 2013, 37, 241-249.	2.1	92
57	Randomized Study of Asunaprevir plus Pegylated Interferon- α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 885-893.	0.6	44

#	ARTICLE	IF	CITATIONS
58	Hepatitis C Viremia Is Associated with Cytomegalovirus IgG Antibody Levels in HIV-Infected Women. PLoS ONE, 2013, 8, e61973.	1.1	3
59	Current and Future Disease Progression of the Chronic HCV Population in the United States. PLoS ONE, 2013, 8, e63959.	1.1	28
60	Incarceration, Community Health, and Racial Disparities. Journal of Health Care for the Poor and Underserved, 2013, 24, 78-88.	0.4	94
61	New Tools in HCV Diagnosis, in Light of the Enhanced Awareness and the New Drugs for Treatment: SMARTube and Stimunology. Scientific World Journal, The, 2013, 2013, 1-12.	0.8	1
62	Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug, Healthcare and Patient Safety, 2014, 6, 37.	1.0	37
63	Hepatitis C Virus Testing in Adults Living with HIV: A Need for Improved Screening Efforts. PLoS ONE, 2014, 9, e102766.	1.1	16
64	Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World Journal of Gastroenterology, 2014, 20, 9633.	1.4	135
66	Editorial Commentary: Hepatitis C Virus Testing and Drug Use in North America; Is There More Than Meets the Eye?. Clinical Infectious Diseases, 2014, 58, 762-764.	2.9	1
67	Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. BMJ Open, 2014, 4, e004318.	0.8	28
68	Costs of telaprevir-based triple therapy for hepatitis C: \$189,000 per sustained virological response. Hepatology, 2014, 60, 1187-1195.	3.6	39
69	Sofosbuvir. Annals of Pharmacotherapy, 2014, 48, 1019-1029.	0.9	52
70	Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men. Clinical Infectious Diseases, 2014, 58, 873-879.	2.9	62
71	Hepatitis C Virus"Related Knowledge and Willingness to Receive Treatment Among Patients on Methadone Maintenance. Journal of Addiction Medicine, 2014, 8, 249-257.	1.4	37
72	Lack of Access to Treatment as a Barrier to HCV Screening. Journal of Public Health Management and Practice, 2014, 20, 420-423.	0.7	6
73	Hepatitis C and Work Impairment. Journal of Clinical Gastroenterology, 2014, 48, 595-599.	1.1	19
74	Treatment of Hepatitis C. JAMA - Journal of the American Medical Association, 2014, 312, 631.	3.8	390
75	Evaluation of a Renal Transplant Program for Incarcerated ESRD Patients. Journal of Correctional Health Care, 2014, 20, 220-227.	0.2	6
76	The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C. JAMA Internal Medicine, 2014, 174, 204.	2.6	113

#	ARTICLE	IF	CITATIONS
77	Age Cohort Differences in Illicit Drug Use and Hepatitis C Among African American Substance Users. <i>Journal of Addictive Diseases</i> , 2014, 33, 314-321.	0.8	4
78	The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care plan. <i>Drug and Alcohol Dependence</i> , 2014, 134, 222-227.	1.6	2
79	Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens. <i>Journal of Clinical Virology</i> , 2014, 59, 223-227.	1.6	43
80	Racial Disparities in the Proportion of Current, Unresolved Hepatitis C Virus Infections in the United States, 2003-2010. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1950-1957.	1.1	13
81	Acute Hepatitis C: Management in the Rapidly Evolving World of HCV. <i>Current Gastroenterology Reports</i> , 2014, 16, 371.	1.1	17
82	Awareness of Biologically Confirmed HCV Among a Community Residing Sample of Drug Users in Baltimore City. <i>Journal of Community Health</i> , 2014, 39, 487-493.	1.9	2
83	Update on Recently Approved Treatments for Hepatitis C. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 211-228.	0.3	7
84	Determining the Involvement and Therapeutic Implications of Host Cellular Factors in Hepatitis C Virus Cell-to-Cell Spread. <i>Journal of Virology</i> , 2014, 88, 5050-5061.	1.5	38
85	Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. <i>Journal of Hepatology</i> , 2014, 60, 530-537.	1.8	118
86	The End of Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 533-536.	2.4	26
87	Estimating the prevalence of hepatitis C infection in New York City using surveillance data. <i>Epidemiology and Infection</i> , 2014, 142, 262-269.	1.0	25
88	Telaprevir-based treatment effects on hepatitis C virus in liver and blood. <i>Hepatology</i> , 2014, 60, 1826-1837.	3.6	22
89	Hepatitis C in African Americans. <i>American Journal of Gastroenterology</i> , 2014, 109, 1576-1584.	0.2	33
90	Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs. <i>BMC Public Health</i> , 2014, 14, 645.	1.2	33
91	Chronic Inflammation and the Role for Cofactors (Hepatitis C, Drug Abuse, Antiretroviral Drug) Tj ETQq0 0 0 rgBT /Qyerlock 10 Tf 50 18	1.1	48
92	Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV mono-infection, a cross-sectional study. <i>BMC Infectious Diseases</i> , 2014, 14, 217.	1.3	10
93	Hepatitis C Screening Trends in a Large Integrated Health System. <i>American Journal of Medicine</i> , 2014, 127, 398-405.	0.6	29
94	Sofosbuvir (Sovaldi) for the treatment of hepatitis C. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 555-566.	1.3	22

#	ARTICLE	IF	CITATIONS
95	Relationship of hepatitis C virus infection with diabetes in the U.S. population. <i>Hepatology</i> , 2014, 60, 1139-1149.	3.6	71
96	Hepatitis C. <i>Disease-a-Month</i> , 2014, 60, 201-212.	0.4	4
97	Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated Populations. <i>Annals of Internal Medicine</i> , 2014, 161, 546.	2.0	77
98	Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA. <i>Epidemiology and Infection</i> , 2014, 142, 1459-1466.	1.0	5
99	Follow-up Testing for Hepatitis C Virus Infection: An Analysis of Massachusetts Surveillance Data, 2007-2010. <i>Public Health Reports</i> , 2014, 129, 403-407.	1.3	0
100	Hepatitis C Seroprevalence among Prison Inmates since 2001: Still High but Declining. <i>Public Health Reports</i> , 2014, 129, 187-195.	1.3	103
101	Assessment of Hepatitis C Risk Factors and Infection Prevalence in a Jail Population. <i>American Journal of Public Health</i> , 2014, 104, 1722-1727.	1.5	24
102	Characteristics and TB treatment outcomes in TB patients with viral hepatitis, New York City, 2000-2010. <i>Epidemiology and Infection</i> , 2015, 143, 1972-1981.	1.0	15
103	A new era of therapy for hepatitis C virus infection. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 471-478.	1.3	17
104	A Birth-cohort testing intervention identified hepatitis c virus infection among patients with few identified risks: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2015, 15, 553.	1.3	10
105	Survey of US Correctional Institutions for Routine HCV Testing. <i>American Journal of Public Health</i> , 2015, 105, 68-71.	1.5	29
106	Turning a page in drug control and public health: advancing HCV/HIV prevention through reform of drug law and policy. <i>Future Virology</i> , 2015, 10, 17-26.	0.9	0
107	Implementing hospital-based baby boomer hepatitis c virus screening and linkage to care: Strategies, results, and costs. <i>Journal of Hospital Medicine</i> , 2015, 10, 510-516.	0.7	43
108	Recent advances in management of the HIV/HCV coinfecting patient. <i>Future Virology</i> , 2015, 10, 981-997.	0.9	4
109	Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. <i>World Journal of Hepatology</i> , 2015, 7, 1843.	0.8	41
110	Hepatitis C, disease and its management: a cost-effectiveness analysis of the new generation oral protease inhibitors. <i>Antiviral Therapy</i> , 2015, 20, 827-833.	0.6	2
111	The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 637.	0.7	5
112	Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv091.	0.4	7

#	ARTICLE	IF	CITATIONS
113	Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009. PLoS ONE, 2015, 10, e0132056.	1.1	8
114	Presence of Rheumatoid Factor during Chronic HCV Infection Is Associated with Expansion of Mature Activated Memory B-Cells that Are Hypo-Responsive to B-Cell Receptor Stimulation and Persist during the Early Stage of IFN Free Therapy. PLoS ONE, 2015, 10, e0144629.	1.1	8
115	Peripheral Blood Mononuclear Cell Gene Expression Remains Broadly Altered Years after Successful Interferon-Based Hepatitis C Virus Treatment. Journal of Immunology Research, 2015, 2015, 1-8.	0.9	6
116	Onset of Celiac Disease after Treatment of Chronic Hepatitis C with Interferon Based Triple Therapy. Case Reports in Hepatology, 2015, 2015, 1-4.	0.4	1
117	Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico. Annals of Hepatology, 2015, 14, 642-651.	0.6	17
119	Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. World Journal of Hepatology, 2015, 7, 1921.	0.8	11
120	Self-Efficacy and Adherence to Antiviral Treatment for Chronic Hepatitis C. Journal of Clinical Gastroenterology, 2015, 49, 76-83.	1.1	24
121	Hepatitis C Management and the Infectious Diseases Physician: A Survey of Current and Anticipated Practice Patterns: Figure 1.. Clinical Infectious Diseases, 2015, 61, 792-794.	2.9	10
122	Hepatitis C Infection in the Elderly. Digestive Diseases and Sciences, 2015, 60, 3170-3180.	1.1	33
123	Costs and absence of HCV-infected employees by disease stage. Journal of Medical Economics, 2015, 18, 691-703.	1.0	19
124	Cancer statistics for Hispanics/Latinos, 2015. Ca-A Cancer Journal for Clinicians, 2015, 65, 457-480.	157.7	397
125	Ultrasound elastography: liver. Abdominal Imaging, 2015, 40, 698-708.	2.0	24
126	Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver International, 2015, 35, 30-36.	1.9	73
127	Is widespread screening for hepatitis C justified?. BMJ, The, 2015, 350, g7809-g7809.	3.0	44
128	Regimens for Cirrhotic Patients. Clinics in Liver Disease, 2015, 19, 657-667.	1.0	0
129	Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. Clinical Therapeutics, 2015, 37, 1713-1725.e3.	1.1	7
130	Current Management of Hepatitis C Virus. Clinics in Liver Disease, 2015, 19, 669-688.	1.0	21
131	The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therapeutic Advances in Gastroenterology, 2015, 8, 298-312.	1.4	90

#	ARTICLE	IF	CITATIONS
132	Increase in Perioperative Complications Following Primary Total Hip and Knee Arthroplasty in Patients With Hepatitis C Without Cirrhosis. <i>Journal of Arthroplasty</i> , 2015, 30, 663-668.	1.5	50
133	Prevalence of Hepatitis C Virus Testing in Cohorts Born Between 1945 and 1965 in the U.S.. <i>American Journal of Preventive Medicine</i> , 2015, 48, e7-e9.	1.6	16
134	Natural History of Hepatitis C. , 2015, , 120-130.		0
135	Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1045-1051.	1.1	21
136	Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study. <i>Journal of Community Health</i> , 2015, 40, 940-947.	1.9	12
137	Comparison of Risk-Based Hepatitis C Screening and the True Seroprevalence in an Urban Prison System. <i>Journal of Urban Health</i> , 2015, 92, 379-386.	1.8	33
138	A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System. <i>Journal of Urban Health</i> , 2015, 92, 635-649.	1.8	18
139	Acute HCV Infection: Diagnosis, Epidemiology and Current Treatment Options. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 113-126.	0.8	0
140	Hepatitis C Virus Antibody Positivity and Predictors Among Previously Undiagnosed Adult Primary Care Outpatients: Cross-Sectional Analysis of a Multisite Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 1145-1152.	2.9	30
141	Prevalence of Major Risk Factors and Use of Screening Tests for Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 637-652.	1.1	60
142	Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. <i>Journal of General Internal Medicine</i> , 2015, 30, 950-957.	1.3	76
143	Lack of Health Insurance Limits the Benefits of Hepatitis C Virus Screening: Insights from the National Health and Nutrition Examination Hepatitis C Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 1126-1133.	0.2	29
144	Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients. <i>Drugs in R and D</i> , 2015, 15, 335-349.	1.1	4
145	Hepatitis C Genotype 3: The Remaining Problem. <i>Current Hepatology Reports</i> , 2015, 14, 267-273.	0.4	0
146	Human rights and access to hepatitis C treatment for people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1072-1080.	1.6	52
147	Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. <i>Journal of Viral Hepatitis</i> , 2015, 22, 409-415.	1.0	26
148	Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy. <i>Clinical Infectious Diseases</i> , 2015, 61, 1825-1830.	2.9	48
149	Immigration and viral hepatitis. <i>Journal of Hepatology</i> , 2015, 63, 515-522.	1.8	114

#	ARTICLE	IF	CITATIONS
150	HIV Infection Status as a Predictor of Hepatitis C Virus RNA Testing in Primary Care. American Journal of Preventive Medicine, 2015, 49, 423-427.	1.6	1
151	Hepatitis C Management and the Infectious Diseases Pharmacist. Clinical Infectious Diseases, 2015, 61, 1201-1202.	2.9	7
152	Epidemiology of Hepatitis C Virus. Gastroenterology Clinics of North America, 2015, 44, 699-716.	1.0	30
153	Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology, 2015, 61, 776-782.	3.6	109
154	The continuum of hepatitis C testing and care. Hepatology, 2015, 61, 783-789.	3.6	64
155	Gene expression analysis in serial liver fine needle aspirates. Journal of Viral Hepatitis, 2015, 22, 64-76.	1.0	8
156	Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. Journal of Viral Hepatitis, 2015, 22, 8-17.	1.0	15
157	A Pilot Study of Rapid Hepatitis C Testing in Probation and Parole Populations in Rhode Island. Journal of Health Care for the Poor and Underserved, 2016, 27, 214-223.	0.4	10
158	Spotlight on grazoprevir—elbasvir once-daily combination and its potential in the treatment of hepatitis C. Drug Design, Development and Therapy, 2016, Volume 10, 2119-2127.	2.0	6
159	Hepatitis C Virus universal screening versus risk based selective screening during pregnancy. Journal of Neonatal-Perinatal Medicine, 2016, 8, 371-378.	0.4	34
160	Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 714-722b.	0.5	17
161	Health Disparities in Hepatitis C Screening and Linkage to Care at an Integrated Health System in Southeast Michigan. PLoS ONE, 2016, 11, e0161241.	1.1	51
162	The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic. Journal of Viral Hepatitis, 2016, 23, 473-478.	1.0	29
163	Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology, 2016, 63, 428-436.	3.6	33
164	Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy, 2016, 36, 203-217.	1.2	22
165	Current Management of Hepatitis C Virus Infection. North Carolina Medical Journal, 2016, 77, 188-193.	0.1	4
166	Chronic Hepatitis B, C, and D. Microbiology Spectrum, 2016, 4, .	1.2	2
167	Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infectious Agents and Cancer, 2016, 11, 53.	1.2	63

#	ARTICLE	IF	CITATIONS
168	Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects. <i>Medicine (United States)</i> , 2016, 95, e4483.	0.4	5
169	Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012-2014. <i>Public Health Reports</i> , 2016, 131, 12-19.	1.3	34
170	Improving Healthcare Systems to Reduce Healthcare Disparities in Viral Hepatitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2776-2783.	1.1	10
171	Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. <i>Value in Health</i> , 2016, 19, 326-334.	0.1	30
172	Cocaine Use May be Associated with Increased Depression in Persons Infected with HIV. <i>AIDS and Behavior</i> , 2016, 20, 345-352.	1.4	12
173	Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 511-521.	2.0	16
174	Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. <i>Journal of Medical Economics</i> , 2016, 19, 795-805.	1.0	17
175	No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1356-1360.	2.4	13
176	Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry. <i>Hepatology International</i> , 2016, 10, 616-623.	1.9	5
177	Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. <i>Hepatology</i> , 2016, 64, 2210-2218.	3.6	5
178	Genotype distribution of hepatitis C virus among Lebanese patients: Results from a major tertiary care center. <i>Gene Reports</i> , 2016, 4, 190-193.	0.4	0
179	Performance of Risk-Based and Birth-Cohort Strategies for Identifying Hepatitis C Virus Infection Among People Entering Prison, Wisconsin, 2014. <i>Public Health Reports</i> , 2016, 131, 544-551.	1.3	14
180	Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2016, 56, 670-676.	0.7	13
181	The Order of Addition of Immunocompromise: The Effects of HIV Infection on Fibrosis Progression Among Hepatitis C Virus-Infected Patients. <i>Journal of Infectious Diseases</i> , 2016, 214, 1134-1136.	1.9	4
182	Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1090-1101.	1.9	18
183	The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain. <i>Health Policy</i> , 2016, 120, 975-981.	1.4	3
184	Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver. <i>Bioanalysis</i> , 2016, 8, 1353-1363.	0.6	12
185	Hepatitis C Treatment in HIV Coinfection: Approaches, Challenges, and Future Opportunities. <i>Current Treatment Options in Infectious Diseases</i> , 2016, 8, 379-399.	0.8	2

#	ARTICLE	IF	CITATIONS
186	Relationship of hepatic fibrosis, cirrhosis, and mortality with cholecystectomy in patients with hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 181-186.	0.8	3
187	Presence of hepatitis C (HCV) infection in Baby Boomers with Medicare is independently associated with mortality and resource utilisation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1060-1068.	1.9	16
188	Disparities in hepatitis C testing in U.S. veterans born 1945-1965. <i>Journal of Hepatology</i> , 2016, 65, 259-265.	1.8	22
189	Behavioral Interventions to Reduce Alcohol Use Among Patients with Hepatitis C: A Systematic Review. <i>Social Work in Public Health</i> , 2016, 31, 565-573.	0.7	9
190	The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. <i>Clinical Infectious Diseases</i> , 2016, 62, 298-304.	2.9	46
191	Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2016, 64, 1027-1032.	1.8	54
192	A Smartphone Application Supporting Recovery from Heroin Addiction: Perspectives of Patients and Providers in China, Taiwan, and the USA. <i>Journal of NeuroImmune Pharmacology</i> , 2016, 11, 511-522.	2.1	26
193	Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm ³ Is More Pronounced Among Women Than Men. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv214.	0.4	6
194	Thumb Site 2 Inhibitors of Hepatitis C Viral RNA-dependent RNA Polymerase Allosterically Block the Transition from Initiation to Elongation. <i>Journal of Biological Chemistry</i> , 2016, 291, 10067-10077.	1.6	15
195	Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. <i>American Journal of Gastroenterology</i> , 2016, 111, 250-260.	0.2	16
196	The Burden of Rehospitalization for Patients With Liver Cirrhosis. <i>Hospital Practice (1995)</i> , 2016, 44, 60-69.	0.5	15
197	Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department. <i>Clinical Infectious Diseases</i> , 2016, 62, 1066-1071.	2.9	43
198	Results of a Rapid Hepatitis C Virus Screening and Diagnostic Testing Program in an Urban Emergency Department. <i>Annals of Emergency Medicine</i> , 2016, 67, 119-128.	0.3	65
199	A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. <i>Journal of Public Health</i> , 2016, 38, 130-137.	1.0	47
200	Age-related Morbidity and Mortality After Transjugular Intrahepatic Portosystemic Shunts. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 360-363.	1.1	11
201	HCV Health Policy Developments in Response to the National Viral Hepatitis Action Plan: A Brief Update. <i>Social Work in Public Health</i> , 2017, 32, 77-81.	0.7	1
202	Infectious Disease Issues in Underserved Populations. <i>Primary Care - Clinics in Office Practice</i> , 2017, 44, 67-85.	0.7	16
203	Retention in buprenorphine treatment is associated with improved HCV care outcomes. <i>Journal of Substance Abuse Treatment</i> , 2017, 75, 38-42.	1.5	32

#	ARTICLE	IF	CITATIONS
204	Family Psychoeducation for Hepatitis C Patients and Their Families: Recommendation for Clinicians. <i>Social Work With Groups</i> , 2017, 40, 202-213.	0.3	2
205	Hepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disorders. <i>Journal of Substance Abuse Treatment</i> , 2017, 78, 37-42.	1.5	8
206	An effectiveness study of group psychoeducation for hepatitis C patients in community clinics. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 679-685.	0.8	10
207	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. <i>Contemporary Clinical Trials</i> , 2017, 57, 58-68.	0.8	13
208	Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010. <i>Clinical Infectious Diseases</i> , 2017, 64, 1573-1581.	2.9	41
209	Hepatitis C infection. <i>Nurse Practitioner</i> , 2017, 42, 14-23.	0.2	1
210	Updated Review of Prevalence of Major Risk Factors and Use of Screening Tests for Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1192-1208.	1.1	64
211	Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. <i>Addictive Disorders and Their Treatment</i> , 2017, 16, S1-S23.	0.5	29
212	Pharmacist-initiated hepatitis C virus screening in a community pharmacy to increase awareness and link to care at the medical center. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, S259-S264.	0.7	21
213	Does Hepatitis C Affect the Clinical and Patient-Reported Outcomes of Primary Total Hip Arthroplasty at Midterm Follow-Up?. <i>Journal of Arthroplasty</i> , 2017, 32, 2779-2782.	1.5	15
214	The Role of e-Health in Optimizing Task-Shifting in the Delivery of Antiviral Therapy for Chronic Hepatitis C. <i>Telemedicine Journal and E-Health</i> , 2017, 23, 870-873.	1.6	10
215	Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 10-16.	0.8	11
216	The Landscape of Patient Access to Direct Acting Antivirals by Payer Within the United States Healthcare System. <i>Current Hepatology Reports</i> , 2017, 16, 192-197.	0.4	0
217	Hepatitis C. <i>Primary Care - Clinics in Office Practice</i> , 2017, 44, 631-642.	0.7	5
218	Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?. <i>Current Hepatology Reports</i> , 2017, 16, 152-157.	0.4	45
219	Correlation Between Serum Cytokines, Interferons, and Liver Functions in Hepatitis C Virus Patients. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 32-38.	0.5	6
220	Clinical Manifestations of Acute and Chronic Hepatitis. , 2017, , 363-374.e4.		0
221	Hepatitis C Virus (HCV) Treatment as Prevention: Epidemic and Cost-Effectiveness Modeling. <i>Handbook of Statistics</i> , 2017, 37, 93-119.	0.4	0

#	ARTICLE	IF	CITATIONS
222	Burden of Chronic Viral Hepatitis and Liver Cirrhosis in Brazil - the Brazilian Global Burden of Disease Study. <i>Annals of Hepatology</i> , 2017, 16, 893-900.	0.6	14
223	Race affects <sc>SVR</sc> 12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00379.	1.1	19
224	A Descriptive Analysis of a Community Clinic Providing Hepatitis C Treatment to Poor and Uninsured Patients. <i>Journal of Community Health</i> , 2018, 43, 725-730.	1.9	6
227	Undiagnosed HIV and HCV Infection in a New York City Emergency Department, 2015. <i>American Journal of Public Health</i> , 2018, 108, 652-658.	1.5	24
228	Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 503-513.	1.1	39
229	Liver Transplantation in Hepatitis C-Infected Patients: Experience From a South American Transplant Center. <i>Transplantation Proceedings</i> , 2018, 50, 493-498.	0.3	1
230	Variability in Baseline Liver Test Values in Clinical Trials: Challenges in Enhancing Drug-Induced Liver Injury Assessment in Subjects with Liver Disease. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 431-457.	0.1	0
231	A Combined Use of Intravoxel Incoherent Motion MRI Parameters Can Differentiate Early-Stage Hepatitis-b Fibrotic Livers from Healthy Livers. <i>SLAS Technology</i> , 2018, 23, 259-268.	1.0	31
232	Breath-hold black-blood T1rho mapping improves liver T1rho quantification in healthy volunteers. <i>Acta Radiologica</i> , 2018, 59, 257-265.	0.5	13
233	Robust Postdonation Blood Screening Under Prevalence Rate Uncertainty. <i>Operations Research</i> , 2018, 66, 1-17.	1.2	20
234	Population-level intervention and information collection in dynamic healthcare policy. <i>Health Care Management Science</i> , 2018, 21, 604-631.	1.5	6
235	The rise of the opioid epidemic and hepatitis C-positive organs: A new era in liver transplantation. <i>Hepatology</i> , 2018, 67, 1600-1608.	3.6	62
236	Toward the elimination of hepatitis C in the United States. <i>Hepatology</i> , 2018, 67, 2449-2459.	3.6	36
237	Age- and Gender-Associated Liver Physiological T1rho Dynamics Demonstrated with a Clinically Applicable Single-Breathhold Acquisition. <i>SLAS Technology</i> , 2018, 23, 179-187.	1.0	15
238	Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States. <i>Liver Transplantation</i> , 2018, 24, 735-743.	1.3	21
239	State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015. <i>Value in Health</i> , 2018, 21, 692-697.	0.1	13
240	Hepatitis C is an Independent Risk Factor for Perioperative Complications and Nonroutine Discharge in Patients Treated Surgically for Hip Fractures. <i>Journal of Orthopaedic Trauma</i> , 2018, 32, 565-572.	0.7	13
241	Epidemiology, Natural History, and Diagnosis of Hepatitis C. , 2018, , 428-445.e8.		1

#	ARTICLE	IF	CITATIONS
242	Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans. <i>Annals of Hepatology</i> , 2018, 17, 413-418.	0.6	18
243	Nursing Interventions on Medication Adherence During Hepatitis C Treatment. <i>Gastroenterology Nursing</i> , 2018, 41, 525-531.	0.2	0
244	Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection. <i>International Journal of Medical Sciences</i> , 2018, 15, 466-474.	1.1	20
245	Optimal Information Collection Policies in a Markov Decision Process Framework. <i>Medical Decision Making</i> , 2018, 38, 797-809.	1.2	3
246	Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. <i>Gastroenterology</i> , 2018, 155, 1154-1163.e3.	0.6	166
247	Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 347-370.	1.9	25
248	Estimating the prevalence of chronic hepatitis C virus infection in New York City, 2015. <i>Epidemiology and Infection</i> , 2018, 146, 1537-1542.	1.0	11
249	Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population. <i>Public Health Reports</i> , 2018, 133, 452-460.	1.3	54
250	Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1608-1616.	1.0	13
251	Economically Efficient Hepatitis C Virus Treatment Prioritization Improves Health Outcomes. <i>Medical Decision Making</i> , 2018, 38, 849-865.	1.2	6
252	Forecasting Hepatitis C liver disease burden on real-life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	1.9	33
253	A role for domain I of the hepatitis C virus NS5A protein in virus assembly. <i>PLoS Pathogens</i> , 2018, 14, e1006834.	2.1	41
254	Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz128.	0.4	13
255	Undetectable Hepatitis C Viral Load Is Associated With Improved Outcomes Following Total Joint Arthroplasty. <i>Journal of Arthroplasty</i> , 2019, 34, 2890-2897.	1.5	17
256	Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 930-939.e9.	2.4	70
257	Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system. <i>PLoS ONE</i> , 2019, 14, e0216459.	1.1	20
258	Caring for Patients With Opioid Use Disorder: What Clinicians Should Know About Comorbid Medical Conditions. <i>Psychiatric Research and Clinical Practice</i> , 2019, 1, 16-26.	1.3	8
259	The preoperative management of Hepatitis C may improve the outcome after total knee arthroplasty. <i>Bone and Joint Journal</i> , 2019, 101-B, 667-674.	1.9	14

#	ARTICLE	IF	CITATIONS
260	Risk Factors Associated with Linkage to Care among Suburban Hepatitis C-Positive Baby Boomers and Injection Drug Users. <i>Infectious Diseases and Therapy</i> , 2019, 8, 417-428.	1.8	5
261	The American Cancer Society 2035 challenge goal on cancer mortality reduction. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 351-362.	157.7	49
262	Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic. <i>Annals of Hepatology</i> , 2019, 18, 304-309.	0.6	28
263	Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States. <i>Annals of Hepatology</i> , 2019, 18, 360-365.	0.6	6
264	HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era. <i>Journal of Public Health</i> , 2019, 41, e283-e289.	1.0	10
265	HIV and HCV screening among trauma patients. <i>International Journal of STD and AIDS</i> , 2019, 30, 663-670.	0.5	2
266	Impact of hepatitis C sustained viral response on cardiovascular diseases: a meta-analysis. <i>Hospital Practice (1995)</i> , 2019, 47, 105-110.	0.5	4
267	Temporal trends in liver cancer mortality by educational attainment in the United States, 2000-2015. <i>Cancer</i> , 2019, 125, 2089-2098.	2.0	12
268	Electronic health record year and country of birth testing and patient navigation to increase diagnosis of chronic viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 911-918.	1.0	9
269	Current Prevalence of Major Cancer Risk Factors and Screening Test Use in the United States: Disparities by Education and Race/Ethnicity. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 629-642.	1.1	122
270	Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection. <i>Journal of Pediatrics</i> , 2019, 207, 90-96.	0.9	35
271	Interprofessional team-based approach to patients with chronic hepatitis C and personality disorder: Three case studies. <i>Archives of Psychiatric Nursing</i> , 2019, 33, 352-357.	0.7	0
272	Improving hepatitis C screening and diagnosis in patients born between 1945 and 1965 in a safety-net primary care clinic. <i>BMJ Open Quality</i> , 2019, 8, e000577.	0.4	5
273	Perceptions of Barriers and Benefits of HCV Treatment and Correlates to Treatment Intention in Methadone Patients. <i>Journal of Health Care for the Poor and Underserved</i> , 2019, 30, 1433-1454.	0.4	3
274	Implementation of Value-based Medicine (VBM) to Patients With Chronic Hepatitis C (HCV) Infection. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 262-268.	1.1	3
275	Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. <i>Hepatology</i> , 2019, 69, 1020-1031.	3.6	374
276	Infectious Disease Issues in Underserved Populations. <i>Physician Assistant Clinics</i> , 2019, 4, 107-125.	0.1	1
277	Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone. <i>Clinical Infectious Diseases</i> , 2019, 69, 323-331.	2.9	50

#	ARTICLE	IF	CITATIONS
278	A Multi-Fidelity Rollout Algorithm for Dynamic Resource Allocation in Population Disease Management. <i>Health Care Management Science</i> , 2019, 22, 727-755.	1.5	5
279	Is disclosure a privilege? Race and disclosure patterns of hepatitis C. <i>Journal of Health Psychology</i> , 2019, 24, 1646-1657.	1.3	2
280	Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 4-12.	0.4	8
281	Test4HepC: Promoting Hepatitis C Testing to Baby Boomers Using Social Media. <i>Health Promotion Practice</i> , 2020, 21, 780-790.	0.9	7
282	Ankle fusion in patients with chronic hepatitis C. <i>Foot and Ankle Surgery</i> , 2020, 26, 151-155.	0.8	2
283	Alcohol Use and Ethnicity Independently Predict Antiretroviral Therapy Nonadherence Among Patients Living with HIV/HCV Coinfection. <i>Journal of Racial and Ethnic Health Disparities</i> , 2020, 7, 28-35.	1.8	2
284	Increased cancer rates in patients with chronic hepatitis C. <i>Liver International</i> , 2020, 40, 685-693.	1.9	22
285	Estimating paediatric hepatitis C prevalence in the United States. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1455-1461.	1.0	2
286	Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States. <i>Scientific Reports</i> , 2020, 10, 20922.	1.6	19
287	Placement of chronically homeless into different types of permanent supportive housing before and after a coordinated entry system: The influence of severe mental illness, substance use disorder, and dual diagnosis on housing configuration and intensity of services. <i>Journal of Community Psychology</i> , 2020, 48, 2410-2427.	1.0	3
288	Resistance to excision determines efficiency of hepatitis C virus RNA-dependent RNA polymerase inhibition by nucleotide analogs. <i>Journal of Biological Chemistry</i> , 2020, 295, 10112-10124.	1.6	8
289	Age- and risk factor-based serologic screening for Hepatitis C virus among an Urban, high-risk population. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1369-1387.	1.0	0
290	A Colocalized Hepatitis C Virus Clinic in a Primary Care Practice Improves Linkage to Care in a High Prevalence Population. <i>American Journal of Medicine</i> , 2020, 133, 705-712.	0.6	9
291	Geographically Focused Collocated Hepatitis C Screening and Treatment in Los Angeles's Skid Row. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3023-3031.	1.1	12
292	Diagnostic Accuracy of Noninvasive Tests to Detect Advanced Hepatic Fibrosis in Patients With Hepatitis C and End-Stage Renal Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2332-2339.e1.	2.4	9
293	A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area. <i>PLoS ONE</i> , 2020, 15, e0228351.	1.1	11
294	Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. <i>Drug Safety</i> , 2021, 44, 133-165.	1.4	19
295	Hemostatic Needles: Controlling Hemostasis Time by a Catecholamine Oxidative Pathway. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 10741-10747.	4.0	17

#	ARTICLE	IF	CITATIONS
296	Hepatitis C Antiviral Treatment Decreases All-Cause Complications After Total Joint Arthroplasty Regardless of the Presence of Fibrosis. <i>Journal of Arthroplasty</i> , 2021, 36, 1551-1555.	1.5	7
297	Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium. <i>Harm Reduction Journal</i> , 2021, 18, 54.	1.3	4
298	Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers. <i>Journal of Substance Abuse Treatment</i> , 2021, 127, 108421.	1.5	5
299	Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center. <i>Hepatology Communications</i> , 2021, 5, 412-423.	2.0	6
300	Surveillance for Hepatitis C. , 2015, , 93-124.		2
301	The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 43-48.	1.0	4
303	Outlier Populations: Individual and Social Network Correlates of Solvent-Using Injection Drug Users. <i>PLoS ONE</i> , 2014, 9, e88623.	1.1	1
304	Hepatitis B and Hepatitis C Reactivation in the Biologic Era. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 240-6.	0.7	15
305	Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. <i>Journal of Clinical and Translational Hepatology</i> , 2015, 3, 140-8.	0.7	27
306	Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 76-82.	0.7	19
307	Diminishing Use of Liver Biopsy among Liver Transplant Recipients for Hepatitis C. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, XX-XX.	0.7	3
308	Estimated prevalence of Hepatitis C Virus infection in Canada, 2011. <i>Canada Communicable Disease Report</i> , 2014, 40, 429-436.	0.6	117
309	The Natural History of Hepatitis C Viral Infection: Clinical Evaluation and Monitoring. <i>Open Medicine Journal</i> , 2016, 3, 52-57.	0.5	3
310	Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. <i>World Journal of Gastroenterology</i> , 2013, 19, 7846.	1.4	74
311	Hepatitis C virus knowledge improves hepatitis C virus screening practices among primary care physicians. <i>World Journal of Hepatology</i> , 2018, 10, 319-328.	0.8	18
312	Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2013, 4, 16.	0.6	26
313	Epidemiologic Studies on Viral Hepatitis: A Short Review. <i>Thrita</i> , 2014, 3, .	0.4	8
314	Implications of Treating Hepatitis C Virus Infection Among Patients Awaiting Cadaveric Liver Transplant: A Single-Center Experience. <i>Experimental and Clinical Transplantation</i> , 2015, 13, 7-10.	0.2	4

#	ARTICLE	IF	CITATIONS
315	Association Between Time to First RNA-Negative Test Result Among People With Hepatitis C Virus Infection and Homelessness or Testing at a Correctional or Substance Use Treatment Facility, New York City. Public Health Reports, 2021, , 003335492110492.	1.3	0
317	Human Diseases Prosecution Among Viral Infection and Food Toxins: A Review. International Journal of Pharmacology, 2013, 9, 390-404.	0.1	2
318	Effect of Differentially Expressed MicroRNAs 602 and 323-5p on Hepatitis C Virus Genotype 1b Viral Load in Infected Liver Cells. Journal of Infectious Disease and Therapy, 2014, 02, .	0.1	1
319	Hepatitis Viruses: Hepatitis C. , 2014, , 765-783.		0
320	Knowledge Deficits about Hepatitis C Prognosis and Treatment Among Non-Gastroenterologists and Medical Students. American Journal of Gastroenterology, 2014, 109, S135.	0.2	0
321	A psychiatric pharmacist in a liver clinic managing treated patients with chronic hepatitis C viral infection. Mental Health Clinician, 2014, 4, 266-270.	0.5	0
323	Direct-Acting Antiviral (DAA) Therapy for Chronic Hepatitis C. Journal of the Nihon University Medical Association, 2016, 75, 251-253.	0.0	0
324	Human MicroRNA-602 Inhibits Hepatitis C Virus Genotype 1b Infection and Promotes Tumor Suppressor Gene Expression in a Hepatoma Cell Line. Journal of Virology & Antiviral Research, 2016, 5, .	0.1	0
325	Chronic Hepatitis B, C, and D. , 0, , 69-95.		0
326	Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection. Open Medicine Journal, 2016, 3, 58-69.	0.5	0
327	Hepatitis C and Psychiatric and Substance Use Disorders Co-morbidities; Caring for People with Hepatitis C: Lessons from the Past that Inform Expectations in the Future. Open Medicine Journal, 2016, 3, 49-51.	0.5	0
328	HCV Drug Resistance. , 2017, , 579-609.		0
329	Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States. Journal of Clinical and Translational Hepatology, 2017, 5, 16-22.	0.7	3
332	Hepatitis C Infection Patterns at a Tertiary Care Center in New York: A Cross-Sectional Study. Cureus, 2018, 10, e2225.	0.2	0
333	Sexually Transmitted Hepatitis. , 2020, , 255-275.		0
334	Frontiers in the treatment of hepatitis C virus infection. Gastroenterology and Hepatology, 2014, 10, 90-100.	0.2	7
335	Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. P and T, 2014, 39, 345-52.	1.0	12
336	Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. North American Journal of Medicine & Science, 2014, 7, 21-27.	3.8	5

#	ARTICLE	IF	CITATIONS
337	Hepatitis C screening. <i>Ochsner Journal</i> , 2014, 14, 664-8.	0.5	13
338	Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico. <i>Puerto Rico Health Sciences Journal</i> , 2014, 33, 177-83.	0.2	2
339	Estimating the true prevalence of hepatitis C in Rhode Island. <i>Rhode Island Medical Journal</i> (2013), 2014, 97, 19-24.	0.2	4
340	Real-world Experience with Sofosbuvir-based Regimens for Chronic Hepatitis C, Including Patients with Factors Previously Associated with Inferior Treatment Response. <i>Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health</i> , 2015, 74, 3-7.	0.4	9
341	Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2016, 12, 293-9.	0.2	13
342	Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Mono-infection Treatment. <i>Gastroenterology and Hepatology</i> , 2014, 10, 706-715.	0.2	0
343	Economic Comparison of Serologic and Molecular Screening Strategies for Hepatitis C Virus. <i>Gastroenterology and Hepatology</i> , 2018, 14, 459-462.	0.2	0
344	Direct Acting Antivirals in Hepatitis C-Infected Kidney Transplant Recipients: Associations with Long-term Graft Failure and Patient Mortality. <i>Pathogens and Immunity</i> , 2020, 5, 275-290.	1.4	1
345	Direct Acting Antivirals in Hepatitis C-Infected Kidney Transplant Recipients: Associations with Long-term Graft Failure and Patient Mortality. <i>Pathogens and Immunity</i> , 2020, 5, 275.	1.4	2
346	High-Risk Injection-Related Practices Associated with anti-HCV Positivity among Young Adults Seeking Services in Three Small Cities in Wisconsin. <i>Substance Use and Misuse</i> , 2022, 57, 665-673.	0.7	0
347	Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	1
348	The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments. <i>Trials</i> , 2022, 23, 354.	0.7	3
349	Risk factors for hepatitis C virus infection at a large urban emergency department. <i>Journal of Viral Hepatitis</i> , 2022, 29, 930-937.	1.0	2
350	Viral blood-borne infections testing and linkage to care cascade among persons who experience homelessness in the United States: a systematic review and meta-analysis. <i>BMC Public Health</i> , 2022, 22, .	1.2	0
351	Total Joint Arthroplasty Should Not Be Delayed in Hepatitis C Patients After Successful Treatment Achieving a Sustained Viral Load. <i>Arthroplasty Today</i> , 2022, 17, 107-113.	0.8	4
352	Fluid overload-associated large B-cell lymphoma with primary biliary cirrhosis: A case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2